Pathology: metastatic/advanced RCC (mRCC) - 1st line (L1); mRCC - L1 - PDL1 negative; mRCC - L1 - PDL1 positive;
metastatic/advanced RCC (mRCC) - 1st line (L1) | mRCC - L1 - PDL1 negative | mRCC - L1 - PDL1 positive | |||||||||||
IMmotion-150 (At - all population), 2018 | IMmotion-150 (AtB - all population), 2018 | IMmotion-151 (all population), 2019 | JAVELIN Renal 101 (all population), 2019 | CheckMate 9ER, 2021 | KEYNOTE-426, 2019 | KEYNOTE-581/CLEAR (PDL1), 2021 | IMmotion-151 (PDL1 <1%) EXPLORATORY, 2019 | IMmotion-150 (At - PDL1>1%), 2018 | IMmotion-151 (PDL1 >1%), 2019 | IMmotion-150 (AtB - PDL1>1%), 2018 | JAVELIN Renal 101( PDL1>1%), 2019 | ||
atezolizumab plus bevacizumab | 5 | T1 | T1 | T1 | T1 | T1 | |||||||
avelumab plus axitinib | 2 | T1 | T1 | ||||||||||
atezolizumab alone | 2 | T1 | T1 | ||||||||||
nivolumab plus cabozantinib | 1 | T1 | |||||||||||
pembrolizumab plus lenvatinib | 1 | T1 | |||||||||||
pembrolizumab plus axitinib | 1 | T1 | |||||||||||
sunitinib | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 |